To add or switch therapy in MPN anemia?

Anemia remains a major challenge in the treatment of myeloproliferative neoplasms, especially for patients receiving ruxolitinib. In this expert roundtable, featuring moderator John Mascarenhas, MD, Mount Sinai; Andrew Kuykendall, MD, Moffitt Cancer Center; and Gabriela Hobbs, MD, Massachusetts General Research Institute, the panel discusses practical strategies for managing anemia, including when to add therapies like luspatercept or consider switching to alternatives such as momelotinib. They walk through real-world scenarios, offering insight into sequencing decisions, trial opportunities, and how to recognize when a treatment change may be necessary.

Watch more of the roundtable series.